Comment
. 2010 Nov 25;363(22):2171-2; author reply 2173-4.
doi: 10.1056/NEJMc1009236.
Retinopathy progression in type 2 diabetes
- PMID: 21105809
- DOI: 10.1056/NEJMc1009236
Item in Clipboard
Comment
Retinopathy progression in type 2 diabetes
N Engl J Med.
.
No abstract available
Comment on
-
Effects of medical therapies on retinopathy progression in type 2 diabetes.N Engl J Med. 2010 Jul 15;363(3):233-44. doi: 10.1056/NEJMoa1001288. Epub 2010 Jun 29. N Engl J Med. 2010. PMID: 20587587 Free PMC article. Clinical Trial.
Similar articles
-
Retinopathy progression in type 2 diabetes.N Engl J Med. 2010 Nov 25;363(22):2172; author reply 2173-4. doi: 10.1056/NEJMc1009236. N Engl J Med. 2010. PMID: 21105807 No abstract available.
-
Retinopathy progression in type 2 diabetes.N Engl J Med. 2010 Nov 25;363(22):2172; author reply 2173-4. doi: 10.1056/NEJMc1009236. N Engl J Med. 2010. PMID: 21105808 No abstract available.
-
Fenofibrate: a new treatment for diabetic retinopathy. Molecular mechanisms and future perspectives.Curr Med Chem. 2013;20(26):3258-66. doi: 10.2174/0929867311320260009. Curr Med Chem. 2013. PMID: 23745548 Review.
-
Fenofibrate and diabetic retinopathy.Lancet. 2008 Mar 1;371(9614):721; author reply 722. doi: 10.1016/S0140-6736(08)60332-3. Lancet. 2008. PMID: 18313494 No abstract available.
-
Vascular endothelium as a target of beraprost sodium and fenofibrate for antiatherosclerotic therapy in type 2 diabetes mellitus.Vasc Health Risk Manag. 2005;1(3):209-15. Vasc Health Risk Manag. 2005. PMID: 17319106 Free PMC article. Review.
Cited by
-
Impact of diabetes-related gene polymorphisms on the clinical characteristics of type 2 diabetes Chinese Han population.Oncotarget. 2016 Dec 20;7(51):85464-85471. doi: 10.18632/oncotarget.13399. Oncotarget. 2016. PMID: 27863428 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
